FDA Brief

Warning letters Food

FDA warning letter to

NS Products, Inc.

High riskIssued May 20, 2021Posted May 26, 2021Center for Food Safety and Applied Nutrition

FDA and FTC warned NS Products that website claims make NaturaCure an unapproved infertility drug.

What happened

FDA reviewed www.naturacure.net in March 2021 and found the company takes orders there for NaturaCure; FTC reviewed the website in May 2021. The letter cites website claims and a customer testimonial saying NaturaCure can treat or cure infertility and related conditions such as endometriosis, uterine fibroids, PCOS, and blocked fallopian tubes. FDA says these claims establish the supplement is intended as a drug, but it is not FDA-approved and lacks adequate directions.

What FDA found

  1. Website claims that NaturaCure cures, treats, or prevents infertility and other conditions make it a drug.

    Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. NaturaCure is a new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.

    Sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The product is misbranded because it lacks adequate directions for use; its intended diseases are not suitable for lay self-treatment.

    Section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  4. Selling the misbranded drug in interstate commerce violates the Act.

    Section 301(a) [21 U.S.C. § 331(a)]
  5. FTC says the advertising claims may lack competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

FDA asks NS Products to reply in writing within 15 working days with the specific steps taken to fix the violations, an explanation of how recurrence will be prevented, and related documents. If corrective actions cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • dietary supplement companies making fertility claims
  • online retailers and affiliate marketers of herbal supplements
  • advertising reviewers handling testimonial-based health claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk